Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

Diane L Nordstrom, Edmund A Rossi, PhD, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2009) 114 (22): 1695.

https://doi.org/10.1182/blood.V114.22.1695.1695

Published: 2009

Journal Articles

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

Pankaj Gupta, Ph.D, Rhona Stein, PhD, Thomas M Cardillo, PhD, Richard R Furman, Susan Chen, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 3738.

https://doi.org/10.1182/blood.V114.22.3738.3738

Published: 2009

Journal Articles

A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to An Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity.

Edmund A Rossi, PhD, Eric Chan, Pankaj Gupta, Ph.D, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2009) 114 (22): 3721.

https://doi.org/10.1182/blood.V114.22.3721.3721

Published: 2009

Journal Articles

Differential Effects of Milatuzumab On Human Antigen-Presenting Cells in Comparison to Malignant B Cells.

Xiaochuan Chen, Ph.D., Rhona Stein, PhD, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 2744.

https://doi.org/10.1182/blood.V114.22.2744.2744

Published: 2009

Journal Articles

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Diane L Nordstrom, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1590.

https://doi.org/10.1182/blood.V112.11.1590.1590

Published: 2008

Journal Articles

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Rhona Stein, PhD, Diana Pilas, Diane L Nordstrom, John Kopinski, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1591.

https://doi.org/10.1182/blood.V112.11.1591.1591

Published: 2008

Journal Articles

Efficient Binding, but Moderate Modulation, of Human Dendritic Cell Functions by Milatuzumab, a Humanized Anti-CD74 Monoclonal Antibody

Xiaochuan Chen, Ph.D., Chien-Hsing Chang, PhD, David Goldenberg, ScD, MD

Blood (2008) 112 (11): 2649.

https://doi.org/10.1182/blood.V112.11.2649.2649

Published: 2008

Journal Articles

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Robert M Sharkey, Ph.D., M. Jules Mattes, Ph.D., Habibe Karacay, Ph.D., Chien-Hsing Chang, PhD, Edmund A Rossi, PhD, William J McBride, Ph.D., David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1588.

https://doi.org/10.1182/blood.V112.11.1588.1588

Published: 2008

Journal Articles

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

David M. Goldenberg, ScD, MD, Robert M. Sharkey, PhD, Habibe Karacay, PhD, Chien-Hsing Chang, PhD, Edmund A. Rossi, PhD, William J. McBride, PhD

Blood (2007) 110 (11): 2344.

https://doi.org/10.1182/blood.V110.11.2344.2344

Published: 2007

Journal Articles

Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

Zhengxing Qu, PhD, Thomas M. Cardillo, PhD, Victoria Shi, MSc, Diana L. Delaney, MSc, Hans J. Hansen, PhD, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD,MD

Blood (2006) 108 (11): 2521.

https://doi.org/10.1182/blood.V108.11.2521.2521

Published: 2006

Journal Articles

Construction and Characterization of a Novel Ribonuclease Immunotoxin Consisting of Two Ranpirnase (Rap) Molecules Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody.

Sailaja S. Vanama, PhD, Puja Sapra, PhD, Hans J. Hansen, PhD, Ivan D. Horak, MD, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2004) 104 (11): 3289.

https://doi.org/10.1182/blood.V104.11.3289.3289

Published: 2004

NARROW

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to An Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity.

Differential Effects of Milatuzumab On Human Antigen-Presenting Cells in Comparison to Malignant B Cells.

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Efficient Binding, but Moderate Modulation, of Human Dendritic Cell Functions by Milatuzumab, a Humanized Anti-CD74 Monoclonal Antibody

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

Construction and Characterization of a Novel Ribonuclease Immunotoxin Consisting of Two Ranpirnase (Rap) Molecules Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only